Bergen, Norway, 8[th ]February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, provides an update on the Company sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and India, following … Read more
Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory lung cancer Bergen, Norway, 29 January 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will today present an update from its Phase II study of bemcentinib in combination with anti-PD-1 therapy pembrolizumab (BGBC008) in refractory non-small cell lung cancer (NSCLC) patients at an oral presentation at the 2020 World Conference on … Read more
Bemcentinib i kombinasjon med pembrolizumab ble godt tolerert og viste lovende klinisk aktivitet i motstandsdyktig lungekreft Bergen, Norge – 29. januar 2021: BerGenBio ASA (OSE: BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, presenterer i dag en oppdatering fra sin fase-II studie av bemcentinib i kombinasjon med anti-PD-1-behandling pembrolizumab (BGBC008) hos pasienter med mostandsdyktig ikke-småcellet lungekreft (NSCLC) ved en muntlig presentasjon … Read more
Bergen, Norway, 27 January 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the fourth quarter 2020 on Wednesday 10 February 2021. A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET. The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will … Read more
Bemcentinib i kombinasjon med pembrolizumab ble godt tolerert og viste lovende klinisk aktivitet i motstandsdyktig lungekreft Oppdaterte interim data vil bli presentert på pasienter i andre linje etter CPI-monoterapi Bergen, Norge – 13. januar 2021: BerGenBio ASA (OSE: BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, vil presentere en oppdatering fra sin fase-II studie av bemcentinib i … Read more
· Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory lung cancer Updated interim data will be presented on second line patients following CPI monotherapy Bergen, Norway, 13[th] January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present … Read more
Bergen, Norway, 12[th] January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a member of the senior management team is presenting at the following virtual conferences: Solebury Trout Management Access Event, 6-15 January 2021 Register for the event here (https://troutaccess.com/investor.php/contact/mailcheck/hash/566554ad12a903f0f24683765aa9ed77) … Read more
Bergen, Norway, 11[th] January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, provides an update on the Company sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and India, following … Read more
Bergen, Norway, 16 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce it has been accepted for an oral presentation at the 2020 World Conference on Lung Cancer Singapore (WCLC), being held from 28-31 January 2021. The oral presentation will … Read more
Bergen, Norway, 9 December 2020 – Extraordinary General Meeting in BerGenBio ASA was held virtually on 9 December 2020 at 16:00 hours (CET). All proposals were resolved as presented in the notice convening the extraordinary general meeting distributed on 18 November 2020, as further set out in the minutes from the extraordinary general meeting attached hereto and available at https://www.bergenbio.com/investors/general- meetings/ (https://www.bergenbio.com/investors/general-%20meetings/) -Ends- For further information, please contact: Richard Godfrey CEO, BerGenBio ASA +47 917 … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.